We are pleased to invite you to read the most viewed papers in 2023 in Cancers (ISSN: 2072-6694) on the topic of cancer drug development. The paper list is as follows:

“An Aminosteroid Derivative Shows Higher In Vitro and In Vivo Potencies than Gold Standard Drugs in Androgen-Dependent Prostate Cancer Models”
by Donald Poirier, Jenny Roy, René Maltais, Cindy Weidmann and Étienne Audet-Walsh
Cancers 2023, 15(11), 3033; https://doi.org/10.3390/cancers15113033
Available online: https://www.mdpi.com/2072-6694/15/11/3033

“Baicalein as Promising Anticancer Agent: A Comprehensive Analysis on Molecular Mechanisms and Therapeutic Perspectives”
by A K M Helal Morshed, Supti Paul, Arafat Hossain, Tuli Basak, Md. Sanower Hossain, Md. Mehedi Hasan, Md. Al Hasibuzzaman, Tanjim Ishraq Rahaman, Md. Abdur Rashid Mia, Pollob Shing et al.
Cancers 2023, 15(7), 2128; https://doi.org/10.3390/cancers15072128
Available online: https://www.mdpi.com/2072-6694/15/7/2128

“Targeting of Tetraspanin CD81 with Monoclonal Antibodies and Small Molecules to Combat Cancers and Viral Diseases”
by Christian Bailly and Xavier Thuru
Cancers 2023, 15(7), 2186; https://doi.org/10.3390/cancers15072186
Available online: https://www.mdpi.com/2072-6694/15/7/2186

“Seaweed-Derived Sulfated Polysaccharides; The New Age Chemopreventives: A Comprehensive Review”
by Prajna Paramita Bhuyan, Rabindra Nayak, Srimanta Patra, Hadi Sajid Abdulabbas, Mrutyunjay Jena and Biswajita Pradhan
Cancers 2023, 15(3), 715; https://doi.org/10.3390/cancers15030715
Available online: https://www.mdpi.com/2072-6694/15/3/715

“Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors”
by Lucía Pérez-Lamas, Alejandro Luna, Concepción Boque, Blanca Xicoy, Pilar Giraldo, Raúl Pérez López, Concepción Ruiz Nuño, Natalia De las Heras, Elvira Mora Casterá, Javier López Marín et al.
Cancers 2023, 15(4), 1045; https://doi.org/10.3390/cancers15041045
Available online: https://www.mdpi.com/2072-6694/15/4/1045

“Therapeutic Strategies to Overcome Fibrotic Barriers to Nanomedicine in the Pancreatic Tumor Microenvironment”
by Hiroyoshi Y. Tanaka, Takuya Nakazawa, Atsushi Enomoto, Atsushi Masamune and Mitsunobu R. Kano
Cancers 2023, 15(3), 724; https://doi.org/10.3390/cancers15030724
Available online: https://www.mdpi.com/2072-6694/15/3/724

“Reviewing the Prospective Pharmacological Potential of Isothiocyanates in Fight against Female-Specific Cancers”
by Shoaib Shoaib, Farheen Badrealam Khan, Meshari A. Alsharif, M. Shaheer Malik, Saleh A. Ahmed, Yahya F. Jamous, Shahab Uddin, Ching Siang Tan, Chrismawan Ardianto, Saba Tufail et al.
Cancers 2023, 15(8), 2390; https://doi.org/10.3390/cancers15082390
Available online: https://www.mdpi.com/2072-6694/15/8/2390

“Naturally Isolated Sesquiterpene Lactone and Hydroxyanthraquinone Induce Apoptosis in Oral Squamous Cell Carcinoma Cell Line”
by Afshan Shams, Ayaz Ahmed, Ajmal Khan, Shariqa Khawaja, Najeeb Ur Rehman, Asma Saleem Qazi, Adnan Khan, Sami Bawazeer, Syed Abid Ali and Ahmed Al-Harrasi
Cancers 2023, 15(2), 557; https://doi.org/10.3390/cancers15020557
Available online: https://www.mdpi.com/2072-6694/15/2/557

“Multi-Fold Computational Analysis to Discover Novel Putative Inhibitors of Isethionate Sulfite-Lyase (Isla) from Bilophila wadsworthia: Combating Colorectal Cancer and Inflammatory Bowel Diseases”
by Muhammad Waqas, Sobia Ahsan Halim, Atta Ullah, Assim Alaa Mohammed Ali, Asaad Khalid, Ashraf N. Abdalla, Ajmal Khan and Ahmed Al-Harrasi
Cancers 2023, 15(3), 901; https://doi.org/10.3390/cancers15030901
Available online: https://www.mdpi.com/2072-6694/15/3/901

“Synthesis of New Chromene Derivatives Targeting Triple-Negative Breast Cancer Cells”
by Aysha Alneyadi, Zohra Nausheen Nizami, Hanan E. Aburawi, Soleiman Hisaindee, Muhammad Nawaz, Samir Attoub, Gaber Ramadan, Nehla Benhalilou, Mazoun Al Azzani, Yassine Elmahi et al.
Cancers 2023, 15(10), 2682; https://doi.org/10.3390/cancers15102682
Available online: https://www.mdpi.com/2072-6694/15/10/2682

You are welcome to submit relevant papers to the journal Cancers.

Cancers Editorial Office